Loading
Ran the large Indian trials that showed a single round of HPV testing halves cervical cancer deaths and that visual oral examination cuts deaths in tobacco users, and led the study behind single-dose HPV vaccination.
Rengaswamy Sankaranarayanan trained at the Cancer Institute (WIA) in Chennai and spent most of his career at the International Agency for Research on Cancer in Lyon, where he headed screening research. He led the Osmanabad cluster-randomised trial (131,746 women), in which one round of HPV testing cut cervical cancer deaths by about half (34 versus 64 deaths; hazard ratio 0.52), the Kerala oral cancer screening trial (191,873 people), which reduced oral cancer deaths by a third among tobacco or alcohol users, and the IARC India HPV vaccine study whose one-dose results underpin the WHO's single-dose recommendation.
| Title | Journal | Year |
|---|---|---|
| HPV screening for cervical cancer in rural India | New England Journal of Medicine | 2009 |
| Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial | The Lancet | 2005 |
| Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India | Lancet Oncology | 2016 |
| Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India | Lancet Oncology | 2021 |
One dose protects. WHO endorsed one- or two-dose schedules in 2022, halving the cost and the logistics of vaccinating girls, which is decisive for India (about 127,500 cervical cancers a year) and for the global elimination target. It also removed the main barrier to India's national programme with its home-made vaccine.
HPV DNA testing is the screening test that saves lives in low-resource settings, even when done once. The result underpins WHO's HPV-first screening guidance and India's operational guidelines, and gives the rationale for self-sampled HPV tests as the route to cervical cancer elimination.
Targeted visual screening of tobacco and alcohol users is a cheap, workable way to cut oral cancer deaths in high-incidence countries, and is the basis for India's national oral cancer screening component. Its effect depends on people attending repeatedly and on treatment being available.
Shares Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), HPV DNA testing and self-sampling, International Agency for Research on Cancer (IARC / WHO).
Shares Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), HPV & HBV vaccination, Cervical cancer.
Shares Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India, IARC India HPV vaccine dose study (one, two or three doses), International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination.
Shares HPV screening for cervical cancer in rural India (Osmanabad), HPV DNA testing and self-sampling, Cervical cancer.
Shares HPV DNA testing and self-sampling, International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination, Cervical cancer.
Shares International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination, Cervical cancer, Head and neck squamous cell carcinoma.
Shares International Agency for Research on Cancer (IARC / WHO), HPV & HBV vaccination, Cervical cancer, Head and neck squamous cell carcinoma.
Shares IARC India HPV vaccine dose study (one, two or three doses), HPV DNA testing and self-sampling, HPV & HBV vaccination, Cervical cancer.